European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - darunavir ethanolate; cobicistat - tablet - 800mg ; 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate; cobicistat - tablet - 300mg ; 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - cobicistat; emtricitabine; tenofovir alafenamide fumarate; darunavir ethanolate - tablet - 150mg ; 200mg ; 10mg ; 800mg

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - lopinavir (amorphous); ritonavir - film coated tablet - 200/50 milligram - direct acting antivirals

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itracap is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - ritonavir; lopinavir - oral solution - 20mg/1ml ; 80mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - ritonavir; lopinavir - tablet - 50mg ; 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - ritonavir; lopinavir - tablet - 25mg ; 100mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

janssen-cilag s.p.a. - rilpivirine - tablets film-coated - 25mg